Sign in

Histotripsy & Liver and biliary tract cancer

Last updated: 19 Nov 2026 incl. AI

Sources: PubMed, ClinicalTrials.gov

Does histotripsy treat liver and biliary tract cancer?

Checked

Posts and adverts say that histotripsy, a treatment using focused sound waves, can treat liver cancer and cancer of the bile ducts.

Some results in people look good, but it is not proven that histotripsy treats liver and biliary tract cancer. 5 new studies in people are running or will start soon, say the trial registers.

What studies show

As of , no study fully proves that histotripsy treats liver and biliary tract cancer. We found 66 published papers on histotripsy and liver and biliary tract cancer. They were published between 2018 and 2026. 12 of them are studies in people. 8 of them followed or compared people without deciding who got it (observational studies). Such studies can show a link, but not that one thing causes the other. At least 303 people took part. None of them was a fair test in which chance decided who got it and who did not. 13 were studies in animals, and none was only in cells in the lab. 17 papers are reviews that sum up other studies. 8 research projects on histotripsy for liver and biliary tract cancer are funded and still running.

Trials in people

One test in 44 people had no comparison group. A one-year follow-up of 47 people found the tumour stayed under control in 63.4% of cases by one way of reading scans. By a later re-reading, it was 90%. 6 serious side effects linked to the device happened within 30 days.

Other studies in people

Some studies looked back at patients already treated. Such studies show a link, not cause and effect. In one study of 21 people, 8 got blood clots in a large liver vein. Most of 71 device reports described serious injury, and 10 reported a death.

Reviews

A review of six studies with 414 people found the treatment reached its target in 97% to 100% of cases. It says long-term results, survival and quality of life are not yet known. Other reviews call the evidence early and uneven.

In animals

In rats with liver tumours, a middle dose destroyed the tumour completely. In mice, treating one tumour slowed an untreated tumour elsewhere. Results in animals do not always hold in people.

Other papers

Case reports describe single patients, who also had other treatments. Two Japanese patients were followed for only 14 and 19 days.

What this means for you

Our verdict: Partly true.

Early tests in people show the tumour stayed under control in many cases. No test has compared it with a group that did not get it, and survival is unknown. Serious side effects such as blood clots were reported, so the claim is partly true.

Do not stop or change your treatment because of a story about histotripsy. A study in people is not proof that it helps you. If you are thinking about histotripsy, talk to your care team first.

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.

We searched 18 scientific databases for research from the last 10 years (since 17 Nov 2016).

Sources

  1. The first full year of histotripsy for liver tumors: Local tumor control and preliminary oncologic efficacy. Surgery 2026. Observational study in people. PubMed
  2. Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumors. Int J Surg 2026. Observational study in people. PubMed
  3. Management and Prevention of Histotripsy-Induced Acute Bland Portal Vein Thrombosis in Histotripsy-Treated Liver Tumors. J Vasc Interv Radiol 2026. Observational study in people. PubMed
  4. Histotripsy versus Established Thermal Ablation Technologies: A Comparative Analysis of FDA MAUDE Adverse Event Reporting Patterns. Radiology 2026. Observational study in people. PubMed
  5. Histotripsy for neuroendocrine liver metastases: Early single-institution outcomes and safety. Surgery 2026. Observational study in people. PubMed
  6. Clinical outcomes of histotripsy for liver malignancies: a systematic review of early clinical evidence. HPB (Oxford) 2026. Review. PubMed
  7. Histotripsy for Liver Malignancies: A Systematic Review of the Existing Literature. J Gastrointest Cancer 2026. Review. PubMed
  8. Histotripsy for Hepatocellular Carcinoma in Asia-Pacific: Current Evidence, Evidence Gaps, and Future Research Priorities. J Hepatocell Carcinoma 2026. Review. PubMed
  9. Where does histotripsy fit into hepatocellular carcinoma care?. Cancer 2026. Review. PubMed
  10. Quantification of Histotripsy Dosage Using Machine Learning-Enhanced Ultrasound Imaging Analysis: Correlation with Histological Outcomes. Acad Radiol 2026. In animals. PubMed
  11. Histotripsy dose impacts tumor cellular damage and treatment outcomes in a preclinical model of hepatocellular carcinoma. Sci Rep 2026. In animals. PubMed
  12. Safe and Effective Histotripsy Ablation of Human Liver Tumors in a Genetically Modified Porcine Model. Cancers (Basel) 2026. In animals. PubMed
  13. Complete response in unresectable HER2+ cholangiocarcinoma with histotripsy and systemic therapy followed by liver transplantation: a case report. Front Oncol 2026. Other paper. PubMed
  14. Integrating Histotripsy into Chemoimmunotherapy for Oligometastatic Recurrent Extrahepatic Cholangiocarcinoma: Case Report. Cardiovasc Intervent Radiol 2026. Other paper. PubMed
  15. First clinical implementation of histotripsy for liver tumors in Japan. Glob Health Med 2026. Other paper. PubMed
  16. Histotripsy in Biliary Tract Cancer. 2026. Study in people. ClinicalTrials.gov
  17. Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma. 2026. Study in people. ClinicalTrials.gov
  18. The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors: One-year Update of Clinical Outcomes. Ann Surg 2025. Study in people. PubMed
  19. The first international experience with histotripsy: a safety analysis of 230 cases. J Gastrointest Surg 2025. Observational study in people. PubMed
  20. Histotripsy of Pancreatic Cancer Liver Metastases: Early Outcomes and Imaging Findings. World J Surg 2025. Observational study in people. PubMed
  21. Histotripsy of Liver Metastases: Short-Term Safety and Imaging Findings. Cardiovasc Intervent Radiol 2025. Observational study in people. PubMed
  22. MRI Coregistered Rodent Histotripsy Array for Orthotopic Liver Models. IEEE Trans Ultrason Ferroelectr Freq Control 2025. In animals. PubMed
  23. The #HOPE4LIVER Single-Arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors. Radiology 2024. Study in people. PubMed
  24. Spatiotemporal local and abscopal cell death and immune responses to histotripsy focused ultrasound tumor ablation. Front Immunol 2023. In animals. PubMed
  25. First-in-man histotripsy of hepatic tumors: the THERESA trial, a feasibility study. Int J Hyperthermia 2022. Study in people. PubMed
  26. The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy. 2021. Study in people. ClinicalTrials.gov
  27. The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK). 2021. Study in people. ClinicalTrials.gov

Frontlight Community

Share what you saw, tried or were told about this claim, and read what others went through. Posts are not medical advice: ask your doctor about your own treatment.

Be the first to share your experience or your question about this claim

Research you can look at next

Open trials and published studies linked to this claim, each with its source and date.

This page explains what research has found so far. It is not medical advice. Talk to your doctor before you start, stop or change any treatment.